MCL-1 antibody (AA 303-325)
Quick Overview for MCL-1 antibody (AA 303-325) (ABIN3031296)
Target
See all MCL-1 (MCL1) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 303-325
-
Purpose
- MCL-1 Antibody
-
Purification
- Antigen affinity
-
Immunogen
- Amino acids 303-325 (RDWLVKQRGWDGFVEFFHVEDLE-human) were used as the immunogen for this MCL-1 antibody.
-
Isotype
- IgG
-
-
-
-
Application Notes
- The stated application concentrations are suggested starting amounts. Titration of the MCL-1 antibody may be required due to differences in protocols and secondary/substrate sensitivity.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Buffer
- 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- After reconstitution, the MCL-1 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
-
-
- MCL-1 (MCL1) (Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1))
-
Alternative Name
- MCL-1
-
Background
- BCL2L3, also known as Myeloid cell leukemia sequence 1, encodes an anti-apoptotic protein, which is a member of the Bcl-2 family. Alternative splicing results in multiple transcript variants. The longest gene product (isoform 1) enhances cell survival by inhibiting apoptosis while the alternatively spliced shorter gene products(isoform 2 and isoform 3) promote apoptosis and are death-inducing. Using the methods of somatic cell hybrid analysis and fluorescence in situ hybridization), the MCL-1 gene is mapped to human 1q21. MCL-1is a critical and specific regulator essential for ensuring the homeostasis of early hematopoietic progenitors. Phosphorylation of MCL-1 directs its interaction with the tumor suppressor protein FBW7, which is the substrate-binding component of a ubiquitin ligase complex. The polyubiquitylation of MCL-1 then targets it for proteasomal degradation. Degradation was blocked in patient-derived tumor cells that lacked FBW7 or had loss-of-function mutations in FBW7, conferring resistance to antitubulin agents and promoting chemotherapeutic-induced polyploidy.
-
UniProt
- Q07820
-
Pathways
- MAPK Signaling
Target
-